147 related articles for article (PubMed ID: 27881356)
21. Potential role of CCND1 G870A genotype as a predictor for urothelial carcinoma susceptibility and muscle-invasiveness in Taiwan.
Lin HH; Ke HL; Hsiao KH; Tsai CW; Wu WJ; Bau DT; Chang LL
Chin J Physiol; 2011 Jun; 54(3):196-202. PubMed ID: 21789902
[TBL] [Abstract][Full Text] [Related]
22. Cyclin D1 G870A polymorphism and lung cancer risk: a meta-analysis.
Liu J; Liao Q; Zhang Y; Sun S; Zhong C; Liu X
Tumour Biol; 2012 Oct; 33(5):1467-76. PubMed ID: 22528945
[TBL] [Abstract][Full Text] [Related]
23. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.
Gautschi O; Hugli B; Ziegler A; Bigosch C; Bowers NL; Ratschiller D; Jermann M; Stahel RA; Heighway J; Betticher DC
Lung Cancer; 2006 Mar; 51(3):303-11. PubMed ID: 16406195
[TBL] [Abstract][Full Text] [Related]
24. Association between cyclin D1 G870A polymorphism and cervical cancer risk: a cumulative meta-analysis involving 2,864 patients and 3,898 controls.
Hu YY; Zheng R; Guo C; Niu YM
Diagn Pathol; 2014 Sep; 9():168. PubMed ID: 25204741
[TBL] [Abstract][Full Text] [Related]
25. Association between
Thakur N; Kumari S; Mehrotra R
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30361291
[No Abstract] [Full Text] [Related]
26. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer.
Wang L; Habuchi T; Takahashi T; Mitsumori K; Kamoto T; Kakehi Y; Kakinuma H; Sato K; Nakamura A; Ogawa O; Kato T
Carcinogenesis; 2002 Feb; 23(2):257-64. PubMed ID: 11872630
[TBL] [Abstract][Full Text] [Related]
27. The association between CCND1 G870A polymorphism and colorectal cancer risk: A meta-analysis.
Xie M; Zhao F; Zou X; Jin S; Xiong S
Medicine (Baltimore); 2017 Oct; 96(42):e8269. PubMed ID: 29049220
[TBL] [Abstract][Full Text] [Related]
28. The influence of cyclin D1 A870G polymorphism on colorectal cancer risk and prognosis in a Turkish population.
Yaylim-Eraltan I; Arikan S; Yildiz Y; Cacina C; Ergen HA; Tuna G; Görmüs U; Zeybek U; Isbir T
Anticancer Res; 2010 Jul; 30(7):2875-80. PubMed ID: 20683026
[TBL] [Abstract][Full Text] [Related]
29. Cyclin D1 polymorphism and the risk of endometrial cancer.
Kang S; Kim JW; Park NH; Song YS; Kang SB; Lee HP
Gynecol Oncol; 2005 May; 97(2):431-5. PubMed ID: 15863141
[TBL] [Abstract][Full Text] [Related]
30. A cyclin D1 (CCND1) gene polymorphism contributes to susceptibility to papillary thyroid cancer in the Turkish population.
Aytekin T; Aytekin A; Maralcan G; Gokalp MA; Ozen D; Borazan E; Yilmaz L
Asian Pac J Cancer Prev; 2014; 15(17):7181-5. PubMed ID: 25227811
[TBL] [Abstract][Full Text] [Related]
31. CCND1 G870A polymorphism interaction with cigarette smoking increases lung cancer risk: meta-analyses based on 5008 cases and 5214 controls.
Duan YZ; Zhang L; Liu CC; Zhu B; Zhuo WL; Chen ZT
Mol Biol Rep; 2013 Jul; 40(7):4625-35. PubMed ID: 23653001
[TBL] [Abstract][Full Text] [Related]
32. Cyclin D1 gene G870A variants and primary brain tumors.
Zeybek U; Yaylim I; Ozkan NE; Korkmaz G; Turan S; Kafadar D; Cacina C; Kafadar AM
Asian Pac J Cancer Prev; 2013; 14(7):4101-6. PubMed ID: 23991960
[TBL] [Abstract][Full Text] [Related]
33. Functional role of CyclinD1 polymorphism (G870A) in modifying susceptibility and overall survival of North Indian lung cancer patients.
Pandey A; Bahl C; Sharma S; Singh N; Behera D
Tumori; 2018 Jun; 104(3):179-187. PubMed ID: 30086699
[TBL] [Abstract][Full Text] [Related]
34. Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study.
Zheng Y; Shen H; Sturgis EM; Wang LE; Eicher SA; Strom SS; Frazier ML; Spitz MR; Wei Q
Carcinogenesis; 2001 Aug; 22(8):1195-9. PubMed ID: 11470749
[TBL] [Abstract][Full Text] [Related]
35. Influence of CCND1 G870A polymorphism on the risk of HBV-related HCC and cyclin D1 splicing variant expression in Chinese population.
Zeng Z; Tu J; Cheng J; Yao M; Wu Y; Huang X; Xie X; Zhang X; Lu F; Chen X
Tumour Biol; 2015 Sep; 36(9):6891-900. PubMed ID: 25851350
[TBL] [Abstract][Full Text] [Related]
36. Cyclin D1 G870A Polymorphism: Relation to the Risk of ALL Development, Prognosis Impact, and Methotrexate Cytotoxicity.
El Menshawy N; El Marghany AB; Sarhan MM; Aladle DA
Asian Pac J Cancer Prev; 2020 Oct; 21(10):2941-2947. PubMed ID: 33112552
[TBL] [Abstract][Full Text] [Related]
37. Effect of cyclin D1 (CCND1) polymorphism on gastric premalignant condition.
Tahara T; Shibata T; Yamashita H; Hirata I; Arisawa T
Clin Chem Lab Med; 2008; 46(12):1696-701. PubMed ID: 19055446
[TBL] [Abstract][Full Text] [Related]
38. Association of cyclin D1 gene polymorphisms with risk of esophageal squamous cell carcinoma in Kashmir Valley: a high risk area.
Hussain S; M Y; Thakur N; Salam I; Singh N; Mir MM; Bhat MA; Siddiqi MA; Das BC; Bharadwaj M
Mol Carcinog; 2011 Jul; 50(7):487-98. PubMed ID: 21268129
[TBL] [Abstract][Full Text] [Related]
39. The association of cyclin D1 G870A and E-cadherin C-160A polymorphisms with the risk of colorectal cancer in a case control study and meta-analysis.
Tan XL; Nieters A; Kropp S; Hoffmeister M; Brenner H; Chang-Claude J
Int J Cancer; 2008 Jun; 122(11):2573-80. PubMed ID: 18196581
[TBL] [Abstract][Full Text] [Related]
40. Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases.
Naidu R; Yip CH; Taib NA
Neoplasma; 2008; 55(2):87-95. PubMed ID: 18237245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
